✦ Medicines in AsiaThin moat

Marubeni (8002) — the future bets

Pharmaceutical distribution in Asia is Marubeni's fastest-growing platform, and it is still under 1% of profit.

In 2025 Marubeni took over Sumitomo Pharma's Asian business1, and pharmaceutical sales became one of its core platforms. Adjusted profit rose from ¥2.0 billion to ¥5.0 billion in the year to March 2026, at a 10% return on invested capital, and the company forecasts ¥10.0 billion for the year to March 20272.

Pharmaceutical sales platform (¥ bn)2.0Yr to Mar 20255.0Yr to Mar 202610.0ForecastMarubeni IR presentation, May 2026
Doubling each year from a small base.

The logic is distribution. Selling medicines in fragmented Asian markets needs regulatory relationships, local sales forces and logistics, which a trading house can build and a drug developer may not want to. The Next Generation Business Development segment, which holds it, earned ¥19.6 billion3.

It is still small: ¥5.0 billion is under 1% of Marubeni's profit.

The same segment also includes Phillips Healthcare in Africa and the electronics businesses Marubeni Techno-Systems and Marubeni Ele-Next4. Next Generation Business Development's profit rose from ¥4.7 billion to ¥19.6 billion5, the fastest growth of any segment.

The measure is the ¥10.0 billion forecast. Doubling again in a year would make it the fastest-growing platform; missing it would make it another small business.

Moat trajectory: Widening

Profit rose two and a half times and is forecast to double again.

The number that tests this moat
Reported
Pharmaceutical sales platform adjusted net profit
¥5.0bn against ¥2.0bn, ¥10.0bn forecast

The fastest-growing platform; the forecast doubling is the test of whether it scales.

Source: Marubeni full-year IR presentation, May 2026 ↗
References
  1. ReportedIn 2025 Marubeni took over Sumitomo Pharma's Asian business, and pharmaceutical sales became one of its core platforms.
    Marubeni Integrated Report 2026, introduction and At a Glance - the company history from 1858 and the market positions the company states for its businesses. — 2026 · publ. 2026 · source ↗
  2. ReportedAdjusted profit rose from ¥2.0 billion to ¥5.0 billion in the year to March 2026, at a 10% return on invested capital, and the company forecasts ¥10.0 billion for the year to March 2027.
    Marubeni Corporation, full-year IR presentation for the fiscal year ended March 31, 2026 - Core Strategic Platform Businesses: adjusted net profit, ROIC, forecasts and growth rates of each platform, and the portfolio ROIC by resources and non-resources. — FY to March 2026 · publ. 1 May 2026 · source ↗
  3. ReportedThe Next Generation Business Development segment, which holds it, earned ¥19.6 billion.
    Marubeni Corporation, Summary of Consolidated Financial Results for the fiscal year ended March 31, 2026 (IFRS) - consolidated statements of profit or loss, financial position and cash flows, the segment note on the ten operating segments with revenue, gross trading profit, operating profit, share of profit of associates, net profit and segment assets, the investments in associates by segment, the one-time items including the Daiichi Life real-estate valuation gain, the dividend and buyback record, and the forecast for the year to March 2027 with its assumptions. — FY to March 2026 · publ. 1 May 2026 · source ↗
  4. ReportedThe same segment also includes Phillips Healthcare in Africa and the electronics businesses Marubeni Techno-Systems and Marubeni Ele-Next.
    Marubeni Corporation, full-year IR presentation for the fiscal year ended March 31, 2026 - net profit of major group companies by segment, with ownership and business descriptions. — FY to March 2026 · publ. 1 May 2026 · source ↗
  5. ReportedNext Generation Business Development's profit rose from ¥4.7 billion to ¥19.6 billion, the fastest growth of any segment.
    Marubeni Corporation, Summary of Consolidated Financial Results for the fiscal year ended March 31, 2026 (IFRS) - consolidated statements of profit or loss, financial position and cash flows, the segment note on the ten operating segments with revenue, gross trading profit, operating profit, share of profit of associates, net profit and segment assets, the investments in associates by segment, the one-time items including the Daiichi Life real-estate valuation gain, the dividend and buyback record, and the forecast for the year to March 2027 with its assumptions. — FY to March 2026 · publ. 1 May 2026 · source ↗
Sources
Generated September 24, 2026